Compass Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Net Income	-42.49	-39.23	-82.18	-29.5	-34.74
Depreciation & Amortization	1.89	1.9	1.62	2.4	2.12
Share-Based Compensation	6.12	5.33	4.03	4.02	0.92
Other Operating Activities	-6.13	-2.13	56.86	-3.72	-0.03
Operating Cash Flow	-40.62	-34.13	-19.67	-26.8	-31.74
Capital Expenditures	-0.03	-0.04	-1.45	0.04	-0.47
Acquisitions	0	0	-0.32	0	0
Change in Investments	27	-151.16	0	0	0
Investing Cash Flow	26.97	-151.2	-1.77	0.04	-0.47
Share Issuance / Repurchase	3.19	76.25	128.27	60.48	0
Debt Issued / Paid	0	0	-9.38	-5.63	0
Other Financing Activities	-0.25	-0.5	-0.28	-6.32	-
Financing Cash Flow	2.94	75.76	118.61	48.54	0
Net Cash Flow	-10.72	-109.57	97.18	21.77	-32.21
Free Cash Flow	-40.65	-34.16	-21.12	-26.77	-32.21
Free Cash Flow Per Share	-0.32	-0.33	-0.34	-0.87	-4.81

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).